Eton Pharmaceuticals commercial chief sells 3,500 shares

Q: How many ETON shares did Ipek Erdogan-Trinkaus sell?

Ipek Erdogan-Trinkaus sold 2,340 shares at a weighted-average $67.1787 per share and 1,160 shares at a weighted-average $67.8785 per share on November 10, 2026. The reported trade-price ranges were $66.645 to $67.62 and $67.6825 to $68.075, respectively.

Q: When do Ipek Erdogan-Trinkaus's ETON options become fully vested and exercisable?

The options vest in 48 equal monthly installments from January 12, 2026, until fully vested and exercisable on January 12, 2030.

Available on EDGAR 11/12/2026 - 04:45 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:45 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. (ETON) Chief Commercial Officer Ipek Erdogan-Trinkaus exercised options for 3,500 common shares on November 10, 2026, at an exercise price of $15.47 per share; 37,155 options were reported following the exercise. That day, she sold 2,340 shares at a weighted-average $67.1787 per share, with reported trade prices ranging from $66.645 to $67.62, and 1,160 shares at a weighted-average $67.8785 per share, with reported trade prices ranging from $67.6825 to $68.075. The filing does not report a Rule 10b5-1 plan.

Insider Trade Summary

Exercise and Sale: 3,500 shares ($182K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Erdogan-Trinkaus Ipek

Role Chief Commercial Officer

Sold 3,500 shs ($236K)

Approx. gross sale proceeds $236K

Approx. exercise cost $54K

Approx. pre-tax spread $182K

Share of Position Sold 46.2%

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option ^F1	3,500	$0.00	$0.00
Exercise	Common Stock	3,500	$15.47	$54K
Sale	Common Stock ^{F2, F3}	2,340	$67.1787	$157K
Sale	Common Stock ^{F2, F4}	1,160	$67.8785	$79K

Holdings After Transaction: Employee Stock Option — 37,155 options (Direct); Common Stock — 4,081 shares (Direct)

Holdings Before and After: Employee Stock Option, 40,655 to 37,155 options (Direct); Common Stock, 4,081 to 4,081 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (4)

F1. The shares subject to the option vest in 48 equal monthly installments from the date of grant (1-12-2026) until fully vested and exercisable on January 12, 2030.
F2. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F3. The shares were sold in multiple trades at prices ranging from $66.645 to $67.62. The price reported above reflects the weighted average sales price.
F4. The shares were sold in multiple trades at prices ranging from $67.6825 to $68.075. The price reported above reflects the weighted average sales price.

Key Figures

Options exercised: 3,500 options Exercise price: $15.47 per share Options following exercise: 37,155 options +2 more

5 metrics

Options exercised 3,500 options November 10, 2026

Exercise price $15.47 per share Options exercised on November 10, 2026

Options following exercise 37,155 options Reported following the November 10, 2026 exercise

Shares sold at first weighted-average price 2,340 shares at $67.1787 per share November 10, 2026; reported trade prices ranged from $66.645 to $67.62

Shares sold at second weighted-average price 1,160 shares at $67.8785 per share November 10, 2026; reported trade prices ranged from $67.6825 to $68.075

Key Terms

weighted average sales price, fully vested and exercisable

2 terms

weighted average sales price financial

"reflects the weighted average sales price"

fully vested and exercisable technical

"until fully vested and exercisable on January 12, 2030"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ETON shares did Ipek Erdogan-Trinkaus sell?

Ipek Erdogan-Trinkaus sold 2,340 shares at a weighted-average $67.1787 per share and 1,160 shares at a weighted-average $67.8785 per share on November 10, 2026. The reported trade-price ranges were $66.645 to $67.62 and $67.6825 to $68.075, respectively.

When do Ipek Erdogan-Trinkaus's ETON options become fully vested and exercisable?

The options vest in 48 equal monthly installments from January 12, 2026, until fully vested and exercisable on January 12, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Erdogan-Trinkaus Ipek

(Last)

(First)

(Middle)

C/O ETON PHARMACEUTICALS, INC.

21925 W. FIELD PARKWAY, SUITE 235

(Street)

DEERPARK

ILLINOIS

60010-7208

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/10/2026		M		3,500	A	$15.47	7,581	D
Common Stock	11/10/2026		S		2,340	D	$67.1787⁽²⁾⁽³⁾	5,241	D
Common Stock	11/10/2026		S		1,160	D	$67.8785⁽²⁾⁽⁴⁾	4,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option	$15.47	11/10/2026		M			3,500	01/12/2026	01/11/2030⁽¹⁾	Common Stock	3,500	$0	37,155	D

Explanation of Responses:

1. The shares subject to the option vest in 48 equal monthly installments from the date of grant (1-12-2026) until fully vested and exercisable on January 12, 2030.

2. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

3. The shares were sold in multiple trades at prices ranging from $66.645 to $67.62. The price reported above reflects the weighted average sales price.

4. The shares were sold in multiple trades at prices ranging from $67.6825 to $68.075. The price reported above reflects the weighted average sales price.

Remarks:

The signing person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.

	/s/ Judith Matthews	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR